優(yōu)化拉米夫定治療慢性乙型肝炎會(huì)議紀(jì)要doc-資料下載頁(yè)
2025-07-17 16:53本頁(yè)面
【正文】 parameters and early response predict therapeutic outes in HBeAgnegative chronic hepatitis B patients treated with telbivudine or lamivudine. Hepatol Int (2008) 2:S77. OL108.13. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001。34(4 pt 1):78591.14. Yuen MF, Fong DY, Wong DK, et al. Predictive value of HBV DNA levels at frequent time points during early and maintenance phase of 5year lamivudine and mutational profiles of reverse transcriptase (RT) and surface (S) genes. Hepatology, 2006, 44 (Suppl 1): 557A.15. Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5year ideal response. Hepatology, 2007。46:1695–703.16. Lampertico. P, , , et al. Four years of Adefovir addon in 145 lamivudine resistant patients with chronic hepatitis B: low risk of genotypic resistance to ADV and prevention of virologic breakthrough. AASLD 2008. Abstract 906. 17. Hadziyannis SJ, Rapti I, Dimou E. Adefovir dipivoxil addon treatment to lamivudine resistant HBeAgnegative chronic hepatitis B patients. 5year followup data of an ongoing prospective study. AASLD 2008. Abstract 924.18. , , , et al. Denovo bination therapy with lamivudine and adefovir effciently controls viral replication in patients with chronic hepatitis B. AASLD 2008, Abstract 930. 7 /
黨政相關(guān)相關(guān)推薦
鄂ICP備17016276號(hào)-1